Commercialisation, Phase II Results & Revenue Path

Imaging Biometrics Limited (LSE: IBAI) is pleased to update shareholders on the EAF151 Phase II clinical trial results presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on 31 May 2026, and to outline the Board's plans to drive revenue growth from its IB Neuro platform.

EAF151 is a prospective, multicentre Phase II study conducted across 33 centres and 146 patients, sponsored by ECOG-ACRIN, part of the US National Clinical Trials Network (NCTN). The study evaluated whether dynamic susceptibility contrast (DSC) MRI-derived cerebral blood volume, computed using IB Neuro, could provide an early and objective biomarker of response to bevacizumab in recurrent glioblastoma (rGBM).

Centralized image processing was performed by the ACRIN core lab. IB Delta T1 (dT1) maps were generated from standard MRI scans for all examinations to objectively delineate true regions of contrast enhancement. IB Neuro was used to compute both normalized and standardized relative cerebral blood volume (nRCBV and sRCBV, respectively). Mean nRCBV and sRCBV values were then calculated within the dT1-defined contrast-enhancing regions.

Both baseline and early (2 week) post-treatment rCBV measurements-whether derived using conventional manual normalization or automated standardized methods-demonstrated meaningful associations with patient outcomes. Notably, IB Neuro's sRCBV, a fully automated and operator-independent output map, unique to IB, showed the strongest statistically significant association with overall survival (OS), outperforming manually normalized rCBV. These findings position EAF151 as one of the first prospective, multicenter trials to validate an automated advanced imaging biomarker for OS prediction in recurrent glioblastoma.

Because bevacizumab is costly and does not benefit all patients, an objective early-response signal has material clinical and economic value: it could help clinicians determine within weeks rather than months whether treatment is working, reducing exposure to ineffective therapy, limiting unnecessary cost, and facilitating earlier transition to alternative treatments. The Board believes this positions IB Neuro as a significant clinical decision-support tool in an under-served and high-cost disease area.

The Group's commercialisation strategy targets both participating EAF151 sites and organizations conducting clinical trials with anti-angiogenic agents-including clinical research organizations (CROs) and trial sponsors-through a combination of direct sales channels and global distribution partners. Early response assessment offers a compelling and immediate value proposition for trial sponsors and clinicians, where timely and data-driven decision-making is critical. The EAF151 results provide prospective clinical validation of this approach, positioning IB Neuro's sRCBV as an operationally practical and readily deployable solution in comparable trial settings and for routine clinical use. Collectively, these opportunities underpin a capital-efficient strategy focused on generating incremental revenue from existing infrastructure without the need for material external funding.

Michael Schmainda, Chief Executive Officer of Imaging Biometrics, LLC (the Group's US operating subsidiary), commented: "The EAF151 results show that the technology built in IB Neuro can provide early, objective signals of treatment response-within weeks rather than months-offering the potential to streamline clinical trials and help clinicians everywhere identify more effective treatment strategies sooner."